Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker - PubMed (original) (raw)
Case Reports
. 1993 Dec 5;268(34):25894-901.
Affiliations
- PMID: 7503990
Free article
Case Reports
Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker
F di Marzo Veronese et al. J Biol Chem. 1993.
Free article
Abstract
The third hypervariable region, or V3 loop, represents the principal neutralizing domain of the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1). Sequential viral isolates from a laboratory worker (LW) accidentally infected with HIV-1IIIB in 1985 were analyzed using type-specific neutralizing monoclonal antibodies directed to the V3 loop. A single amino acid substitution, Ala-->Thr at position 21 in the V3 loop of HIV-1LW isolated in 1987, was shown to determine the loss of the neutralizing epitope recognized by one of the monoclonal antibodies (M77). However, this antibody efficiently recognized linear V3 loop peptides containing either the Ala or Thr residue at position 21, indicating that a local change in conformation was responsible for the epitope loss in the native gp120. Molecular modeling studies, experimentally supported by different amino acid replacements at position 21, indicated that the Ala-->Thr substitution leads to a drastic change in the domain of the V3 loop, which contains the complementary surface for antibody binding. These results provide evidence for the first time that a conformation-dependent epitope within the V3 loop of HIV-1 is involved in the generation of neutralization escape mutants in vivo.
Similar articles
- Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE. Lusso P, et al. J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005. J Virol. 2005. PMID: 15890935 Free PMC article. - Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW. Nakamura GR, et al. J Virol. 1993 Oct;67(10):6179-91. doi: 10.1128/JVI.67.10.6179-6191.1993. J Virol. 1993. PMID: 7690420 Free PMC article. - Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R, Qin Y, Banasik M, Lees W, Shepherd AJ, Cho MW, Kong XP. Pan R, et al. J Virol. 2018 Mar 14;92(7):e01894-17. doi: 10.1128/JVI.01894-17. Print 2018 Apr 1. J Virol. 2018. PMID: 29343576 Free PMC article. - Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
Robert-Guroff M, Louie A, Myagkikh M, Michaels F, Kieny MP, White-Scharf ME, Potts B, Grogg D, Reitz MS Jr. Robert-Guroff M, et al. J Virol. 1994 Jun;68(6):3459-66. doi: 10.1128/JVI.68.6.3459-3466.1994. J Virol. 1994. PMID: 7514675 Free PMC article.
Cited by
- Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential.
Velappan N, Biryukov SS, Rill NO, Klimko CP, Rosario-Acevedo R, Shoe JL, Hunter M, Dankmeyer JL, Fetterer DP, Bedinger D, Phipps ME, Watt AJ, Abergel RJ, Dichosa A, Kozimor SA, Cote CK, Lillo AM. Velappan N, et al. PLoS One. 2024 Jul 2;19(7):e0305034. doi: 10.1371/journal.pone.0305034. eCollection 2024. PLoS One. 2024. PMID: 38954719 Free PMC article. - Healthy humans can be a source of antibodies countering COVID-19.
Velappan N, Nguyen HB, Micheva-Viteva S, Bedinger D, Ye C, Mangadu B, Watts AJ, Meagher R, Bradfute S, Hu B, Waldo GS, Lillo AM. Velappan N, et al. Bioengineered. 2022 May;13(5):12598-12624. doi: 10.1080/21655979.2022.2076390. Bioengineered. 2022. PMID: 35599623 Free PMC article. - Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design.
Jaiswal V, Lee HJ. Jaiswal V, et al. Front Immunol. 2022 Apr 4;13:832106. doi: 10.3389/fimmu.2022.832106. eCollection 2022. Front Immunol. 2022. PMID: 35444664 Free PMC article. - Development of Anti-Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications.
Lillo AM, Velappan N, Kelliher JM, Watts AJ, Merriman SP, Vuyisich G, Lilley LM, Coombs KE, Mastren T, Teshima M, Stein BW, Wagner GL, Iyer S, Bradbury ARM, Harris JF, Dichosa AE, Kozimor SA. Lillo AM, et al. Immunotargets Ther. 2020 Nov 27;9:299-316. doi: 10.2147/ITT.S267077. eCollection 2020. Immunotargets Ther. 2020. PMID: 33294421 Free PMC article. - Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE. Lusso P, et al. J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005. J Virol. 2005. PMID: 15890935 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical